

Resource Summary Report

Generated by [RRID](#) on Aug 1, 2026

Purified (azide-free) anti-TDP43 Phospho (Ser409/410)

RRID:AB_2564934

Type: Antibody

Proper Citation

BioLegend Cat# 829901, RRID:AB_2564934

Antibody Information

URL: http://antibodyregistry.org/AB_2564934

Proper Citation: BioLegend Cat# 829901, RRID:AB_2564934

Target Antigen: TDP43 Phospho Ser409/410

Host Organism: Rat

Clonality: monoclonal

Comments: Applications: WB, IHC, ICC, ELISA

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Purified (azide-free) anti-TDP43 Phospho (Ser409/410)

Description: This monoclonal targets TDP43 Phospho Ser409/410

Target Organism: rat, human

Clone ID: Clone 1D3/TDP-43

Antibody ID: AB_2564934

Vendor: BioLegend

Catalog Number: 829901

Record Creation Time: 20250819T225823+0000

Record Last Update: 20250820T035320+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Purified (azide-free) anti-TDP43 Phospho (Ser409/410).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Guo L, et al. (2026) Defining RNA oligonucleotides that reverse deleterious phase transitions of RNA-binding proteins with prion-like domains. *Molecular cell*, 86(1), 114.

Selmanovic E, et al. (2025) Chronic traumatic encephalopathy neuropathologic change in the Late Effects of Traumatic Brain Injury project: Findings in a community autopsy cohort. *Journal of neuropathology and experimental neurology*, 84(12), 1174.

Dubey SK, et al. (2025) Aberrant nuclear pore complex degradation contributes to neurodegeneration in VCP disease. *Neuron*.

Shahidehpour RK, et al. (2025) Assessing Co-Localization of ITM2B With Alzheimer's Disease and Limbic-Predominant Age-Related TDP-43 Encephalopathy Neuropathologic Changes. *Neuropathology : official journal of the Japanese Society of Neuropathology*, 45(4), e70003.

Rummens J, et al. (2025) TDP-43 seeding induces cytoplasmic aggregation heterogeneity and nuclear loss of function of TDP-43. *Neuron*, 113(10), 1597.

Evangelista BA, et al. (2025) ALS-associated TDP-43 aggregates drive innate and adaptive immune cell activation. *iScience*, 28(6), 112648.

Alessandrini F, et al. (2025) TDP-43 dysfunction compromises UPF1-dependent mRNA metabolism in ALS. *Neuron*.

Lin NH, et al. (2023) Neuroprotective Effects of a Multi-Herbal Extract on Axonal and Synaptic Disruption in Vitro and Cognitive Impairment in Vivo. *Journal of Alzheimer's disease reports*, 7(1), 51.

Wani A, et al. (2021) Neuronal VCP loss of function recapitulates FTLD-TDP pathology. Cell reports, 36(3), 109399.

Gasset-Rosa F, et al. (2019) Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. Neuron, 102(2), 339.